Home > Insider Trading > Filing (0001235802-22-000101)

Filing Details

Accession Number:: 0001235802-22-000101
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-08-17 17:28:24
Reporting Period:: 2022-08-15

Accepted Time:: 2022-08-17 17:28:24
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1453593	Xtant Medical Holdings Inc.	XTNT	Biological Products, (No Disgnostic Substances) (2836)	205313323

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1692661	D Kevin Brandt	664 Cruiser Lane Belgrade MT 59714	Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, $0.000001 Par Value	Acquisiton	2022-08-15	410,079	$0.00	726,571	No	4	A	Direct
Common Stock, $0.000001 Par Value	Disposition	2022-08-16	18,700	$0.49	707,871	No	4	S	Direct
Common Stock, $0.000001 Par Value	Disposition	2022-08-17	4,300	$0.48	703,571	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

These shares will vest and be issued with respect to 102,520 shares on each of August 15, 2023, August 15, 2024 and August 15, 2025 and with respect to 102,519 shares on August 15, 2026 pursuant to a restricted stock unit granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan.
Includes 588,046 shares that will be issued over time subject to vesting pursuant to restricted stock units granted under the Xtant Medical Holdings, Inc. Amended and Restated 2018 Equity Incentive Plan.
These shares were sold under a pre-arranged sales instruction pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, to cover the estimated tax withholding obligations in connection with the vesting of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.47161 to $0.52, inclusive. The reporting person undertakes to provide to Xtant Medical Holdings, Inc., any security holder of Xtant Medical Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.47 to $0.4953, inclusive. The reporting person undertakes to provide to Xtant Medical Holdings, Inc., any security holder of Xtant Medical Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.